CytomX Therapeutics Reports 2023 Financial Results and

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase...

Related Keywords

United States ,Stephanie Ascher ,Chris Ogden ,Sean Mccarthy ,Bristol Myers Squibb ,Twitter ,Amgen ,Linkedin ,Nasdaq ,Cytomx Therapeutics Inc ,Drug Administration ,Quarter Business Highlights ,Investigational New Drug ,Bayesian Optimal Interval ,Key Milestones ,Annual Report ,Cytomx Therapeutics ,Media Contact ,Ended December ,Nasdaq Ctmx ,Ytomx Therapeutics Inc ,